Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

Clinical trial NCT02616029 · COMPLETED

Trial details

NCT number: NCT02616029
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HIV-1 Infection

Start date: 2015-12-17
Primary completion: 2018-10-11
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.